tirzepatide chronic kidney disease trial An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study

20.94

★★★★☆4.8 (126)

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

22.90

★★★★★4.9 (98)

Weight Loss Injections for Chronic Kidney Disease Patients: A UK Clinical Guide (2026)

21.85

★★★★★5.0 (157)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

29.51

★★★★★4.7 (84)

Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes

24.52

★★★★★4.9 (203)

What Is Tirzepatide Used for? Approved and Potential Uses

26.41

★★★★★5.0 (176)

Can tirzepatide (Zepbound) be used in a patient with chronic kidney disease and an estimated glomerular filtration rate of 28 mL/min/1.73 m², and what dosing and monitoring recommendations are appropriate?

21.80

★★★★★4.8 (132)